Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.5992 USD -2.11% Market Closed
Market Cap: 136.3m USD
Have any thoughts about
Vaxart Inc?
Write Note

Vaxart Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vaxart Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Vaxart Inc
NASDAQ:VXRT
Depreciation & Amortization
$8.9m
CAGR 3-Years
32%
CAGR 5-Years
20%
CAGR 10-Years
15%
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.4B
CAGR 3-Years
-1%
CAGR 5-Years
34%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
$5.6B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$219.7m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$469.5m
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
25%
No Stocks Found

Vaxart Inc
Glance View

Market Cap
136.3m USD
Industry
Biotechnology

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

VXRT Intrinsic Value
0.6663 USD
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Vaxart Inc's Depreciation & Amortization?
Depreciation & Amortization
8.9m USD

Based on the financial report for Sep 30, 2024, Vaxart Inc's Depreciation & Amortization amounts to 8.9m USD.

What is Vaxart Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
15%

Over the last year, the Depreciation & Amortization growth was 9%. The average annual Depreciation & Amortization growth rates for Vaxart Inc have been 32% over the past three years , 20% over the past five years , and 15% over the past ten years .

Back to Top